
Sign up to save your podcasts
Or


Bryah Resources: An Overview
Company and Operations
Market Insights
Joint Ventures and Projects
CEO Insights and Resilience
This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.
Today I chat with Steven Yatomi-Clarke around Prescient Therapeutics.
Steven delves in to the history of the business , the growth of the portfolio and the importance of PTX-100 to the business.
Steven talks about the importance of PTX-100 , the process of design, the testing, how it works and also how meaningful the future results are.
Steven also talks about the timeline of broader advances in medicine, the time, the effort as well as trends in AI.
This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.
Sub 11 Uncovered Series: Episode 1 with James Morrell Co-founder of Muval
Tim and I sit down at Airtasker's Global HQ in Sydney to discuss the origins of Airtasker, the global ambitions, the challenges, the highs the lows as well as some advice for entrepreneurs.
This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.
In this episode I chat with Tom Millner from Contact. Contact manages two funds - ASX listed BKI Investments as well as the Contact Australian Ex-50 fund.
Tom talks about the history of Contact, some of their existing investments, the importance of dividends, the current market conditions as well as some of his stories around hits and misses with various investments.
Content was obtained as Fact from 16/01/2024 - BKI Investor Presentation - HY24 Results
This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.
From the publisher's feed